Helvoet Pharma - company profile

Published: 14-Nov-2008
Ingredients Packaging

Helvoet Pharma is a leading manufacturer of rubber closures and aluminium caps.

Helvoet Pharma is a leading manufacturer of rubber closures and aluminium caps.

With five rubber manufacturing plants and four plants for the production of aluminium seals and flipcaps in Europe and the US, more than 12 billion components are supplied to a global customer base. This makes Helvoet Pharma a worldwide key supplier to pharmaceutical, biotech, medical device and diagnostic markets.

Product range includes :

  • Injection, serum and lyophilisation stoppers
  • Prefilled syringe components
  • Aluminium caps
  • Flip caps
  • Injection sites, sleeve stoppers and connectors
  • Ultra low extractables (FM457) and low moisture (FM460) compounds
  • Packaging components in Ready-for-Sterilisation and Ready-for-Use
  • Coated closures: omniflex 3G
  • Coated Plungers for Prefilled Syringes: OCP

www.omniflex3g.com

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

Read more
As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence

Trending Articles

  1. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  2. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  3. Aenova Group In Europe and worldwide, Aenova is one of the leading contract development and manufacturing organisations (CDMO). The range of services covers the entire value chain of development and production of all common dosage forms (solid, semi-solid and liquid, sterile and non-sterile; high potency and low dosage) and product groups in drugs and food supplements for human and animal health
  4. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    From approval to access: the strategic role of packaging in drug launch success In today’s increasingly complex pharmaceutical landscape, securing regulatory approval is only one milestone on the journey to market

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

From approval to access: the strategic role of packaging in drug launch success

In today’s increasingly complex pharmaceutical landscape, securing regulatory approval is only one milestone on the journey to market
Packaging

Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial

Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study
Ingredients

FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars

The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Subscribe now